Medical device company evaluates of the SENSEI® Laparoscopic Tethered Gamma Probe in Prostate Cance

Photo by Jim Carroll

The company Lightpoint Medical Limited is conducting the clinical trial Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer (LPM-012).

Patients scheduled for RP and ePLND using the standard treatment pathways at each centre will have preoperative 99mTc-nanocolloid imaging. RP and ePLND will be conducted as standard of care, with SLNB guided by the SENSEI® laparoscopic tethered gamma probe carried out after RP and prior to ePLND.

Actual study start date is September 16, 2020. The researchers expect to complete the study by August 2021.

The population that can be enrolled into this study includes the male patients who are 18 or more years of age with histologically proven prostate cancer and patients who are scheduled for radical prostatectomy with ePLND.

The population that are excluded from participation: patients who have received prior prostate cancer treatment or prior pelvic surgery and who have an existing medical condition that would compromise their participation in the study. There are other exclusion criteria.

Among the countries in which the study will be conducted: Belgium, France, Germany and Spain.

Detailed information can be found on the clinical trial page here: https://ichgcp.net/clinical-trials-registry/NCT04632251